On August 7 2023, INHIBRX ($NASDAQ:INBX) released its earnings report for the second quarter of fiscal year 2023 (ending June 30 2023). The company experienced a 95.8% decrease in total revenue compared to the same quarter the previous year, amounting to USD 0.0 million. However, there was an increase in net income, which rose from USD -37.7 million to USD -47.0 million.
The stock opened at $20.8 and closed at $19.3, a drop of 6.2% from the prior closing price of $20.6. Overall, the earnings results were not met with much enthusiasm from investors, and the stock price fell as a result. While INHIBRX’s revenue and dividend increases were promising indicators, investors likely wanted to hear more about the company’s plans to continue expanding their business in order to increase their long-term prospects. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Inhibrx. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inhibrx. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inhibrx. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Inhibrx are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Inhibrx Intrinsic Value Calculation
At GoodWhale, we have thoroughly assessed the fundamentals of INHIBRX Inc. and we believe that the intrinsic value of INHIBRX shares is approximately $5.8. We have calculated this intrinsic value using our proprietary Valuation Line. However, the share price of INHIBRX is currently at $19.3, which is an overvaluation by 234.7%. It is clear that there is a significant mispricing of INHIBRX’s stock. More…
Risk Rating Analysis
Star Chart Analysis
The company’s lead product candidate is INBRX-109, a monoclonal antibody (mAb) for the treatment of autoimmune diseases. INBRX-109 is currently in Phase I clinical trials. The company’s other product candidates include INBRX-402, a mAb for the treatment of cancer, and INBRX-503, a mAb for the treatment of infectious diseases. Inhibrx Inc’s main competitors are Alaunos Therapeutics Inc, Nanobiotix SA, Zymeworks Inc. All of these companies are engaged in the business of discovering and developing proprietary biologics to treat serious diseases.
– Alaunos Therapeutics Inc ($NASDAQ:TCRT)
Alaunos Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of therapies for the treatment of cancer. The company’s market cap is 250.77M as of 2022 and has a Return on Equity of -72.28%. The company is headquartered in San Diego, California.
Nanobiotix is a clinical-stage nanomedicine company that is developing new ways to treat cancer. The company’s lead product is NBTXR3, a nanoparticle that is designed to specifically target and destroy cancer cells while leaving healthy cells unharmed. Nanobiotix is currently testing NBTXR3 in several clinical trials for a variety of different cancer types.
Nanobiotix has a market cap of 141.07M as of 2022 and a Return on Equity of -186.52%. The company’s lead product, NBTXR3, is currently being tested in several clinical trials for a variety of different cancer types.
Zymeworks Inc is a clinical-stage biopharmaceutical company that discovers, develops and commercializes multifunctional therapeutics. The company’s key products include ZW25, ZW49 and ZW33. Zymeworks’ products are designed to target multiple disease-associated proteins simultaneously. The company’s products are based on its proprietary technology platform, which enables the design of therapeutics that can be used to treat a range of diseases.
INHIBRX reported disappointing earnings results for the second quarter of FY2023. Total revenue for the quarter amounted to USD 0.0 million, a 95.8% decrease compared to the same quarter the previous year. The company reported net income of USD -47.0 million, an increase from the USD -37.7 million reported the prior year. The stock price responded negatively to this news, and investors should be wary of the company’s weak financial performance.
It is essential to monitor the company’s performance in the coming quarters to determine if its financial performance is stabilizing. Investors should consider any potential risks before investing in INHIBRX.